Abstract: A computing system can be provided for building containerized layers using publish-subscribe topics to facilitate software application data consumption. For example, the computing system may receive data that satisfies a set of data parameters using a publish-subscribe topic. The publish-subscribe topic can be a logical channel for receiving data streams with the data from computing nodes in a distributed computing environment. The computing system can then assemble one or more containerized layers, which can include the data. Additionally, the computing system can deploy the one or more containerized layers in a container at one of the computing nodes.

Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, imidazotriazine, benzoimidazole, benzotriazole, benzoisoxazole, purine, indazole, triazolotriazine, triazolopyridazine, triazolopyrimidine, triazolopyrazine, triazolotetrazine, triazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolopyridazine, pyrazolotriazine, pyrazolopyridine, isoxazolopyrazine, isoxazolopyrimidine, isoxazolopyrdiazine, isoxazolotriazine, or isoxalopyridine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes, glioblastoma, autoimmune diseases, cancer (e.g., glioblastoma, prostate cancer), inflammatory disorders (e.g., airway inflammation), and other diseases.

Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, imidazotriazine, benzoimidazole, benzotriazole, benzoisoxazole, purine, indazole, triazolotriazine, triazolopyridazine, triazolopyrimidine, triazolopyrazine, triazolotetrazine, triazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolopyridazine, pyrazolotriazine, pyrazolopyridine, isoxazolopyrazine, isoxazolopyrimidine, isoxazolopyrdiazine, isoxazolotriazine, or isoxalopyridine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes, glioblastoma, autoimmune diseases, cancer (e.g., glioblastoma, prostate cancer), inflammatory disorders (e.g., airway inflammation), and other diseases.

Abstract: A delta between a first version of a software application and a second version of the software application is determined, the delta including a plurality of delta binary values that identify a difference between the first version of the software application and the second version of the software application. A first plurality of qubits are encoded with a primary software application version that is one of the first version of the software application or the second version of the software application. Qubit metadata that refers to a second plurality of qubits is generated based on the delta, the second plurality of qubits including at least some of the first plurality of qubits The second version of the software application is generated from the first plurality of qubits, the second plurality of qubits and the qubit metadata.

Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, imidazotriazine, benzoimidazole, benzotriazole, benzoisoxazole, purine, indazole, triazolotriazine, triazolopyridazine, triazolopyrimidine, triazolopyrazine, triazolotetrazine, triazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolopyridazine, pyrazolotriazine, pyrazolopyridine, isoxazolopyrazine, isoxazolopyrimidine, isoxazolopyrdiazine, isoxazolotriazine, or isoxalopyridine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes, glioblastoma, autoimmune diseases, cancer (e.g., glioblastoma, prostate cancer), inflammatory disorders (e.g., airway inflammation), and other diseases.

Abstract: A continuous optimizer detects a code promotion of a candidate release of an application. In response to the code promotion, the continuous optimizer instantiates a JVM and profiles the application to obtain a JVM profile. The continuous optimizer benchmarks the candidate release against the JVM and JVM profile. The continuous optimizer further compares the benchmark results with previous benchmark results. Based upon the comparison and a set of rules, the continuous optimizer causes the candidate release to be promoted.

Abstract: A continuous optimizer detects a code promotion of a candidate release of an application. In response to the code promotion, the continuous optimizer instantiates a JVM and profiles the application to obtain a JVM profile. The continuous optimizer benchmarks the candidate release against the JVM and JVM profile. The continuous optimizer further compares the benchmark results with previous benchmark results. Based upon the comparison and a set of rules, the continuous optimizer causes the candidate release to be promoted.

Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, imidazotriazine, benzoimidazole, benzotriazole, benzoisoxazole, purine, indazole, triazolotriazine, triazolopyridazine, triazolopyrimidine, triazolopyrazine, triazolotetrazine, triazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolopyridazine, pyrazolotriazine, pyrazolopyridine, isoxazolopyrazine, isoxazolopyrimidine, isoxazolopyrdiazine, isoxazolotriazine, or isoxalopyridine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes, glioblastoma, autoimmune diseases, cancer (e.g., glioblastoma, prostate cancer), inflammatory disorders (e.g., airway inflammation), and other diseases.

Abstract: An image quality control system is disclosed. The example system includes an artificial intelligence modeler to process image data and metadata from patient data to generate first feature(s) from the image data and to parse the metadata to identify study information. The example system includes a computer vision processor to identify second feature(s) in the image data. The example system includes a results evaluator to compare the first feature(s) and second feature(s) to generate a comparison and to evaluate the comparison, first feature(s), and second feature(s) with respect to the study information to generate an evaluation. The example system includes a quality controller to compare the evaluation to quality criterion(-ia) to produce an approval or rejection of the patient data, the approval to trigger release of the patient data and the rejection to deny release of the patient data.

Abstract: An image quality control system is disclosed. The example system includes an artificial intelligence modeler to process image data and metadata from patient data to generate first feature(s) from the image data and to parse the metadata to identify study information. The example system includes a computer vision processor to identify second feature(s) in the image data. The example system includes a results evaluator to compare the first feature(s) and second feature(s) to generate a comparison and to evaluate the comparison, first feature(s), and second feature(s) with respect to the study information to generate an evaluation. The example system includes a quality controller to compare the evaluation to quality criterion(-ia) to produce an approval or rejection of the patient data, the approval to trigger release of the patient data and the rejection to deny release of the patient data.

Abstract: This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazopyridine, imidazopyrimidine, imidazopyrazine, imidazopyridazine, imidazotriazine, benzoimidazole, benzotriazole, benzoisoxazole, purine, indazole, triazolotriazine, triazolopyridazine, triazolopyrimidine, triazolopyrazine, triazolotetrazine, triazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolopyridazine, pyrazolotriazine, pyrazolopyridine, isoxazolopyrazine, isoxazolopyrimidine, isoxazolopyrdiazine, isoxazolotriazine, or isoxalopyridine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes, glioblastoma, autoimmune diseases, cancer (e.g., glioblastoma, prostate cancer), inflammatory disorders (e.g., airway inflammation), and other diseases.

Abstract: Novel tools and techniques for determining suitability and/or desirability of a prospective residence for a user. In some embodiments, a computer might receive a list of real estate listings, each pertaining to, and including a plurality of attributes about, an available home. The computer might collect information about factors relating to a user, generate a user profile based at least in part on the factors, and infer a prioritized list of real estate listing characteristics to satisfy the user based on a prioritized list of user criteria. The computer might subsequently generate and prioritize a list of potential homes from the list of real estate listings, based on comparisons, and at least in part on matches, between the prioritized list of real estate listing characteristics and attributes of at least some potential homes in the listings. The computer might subsequently display the prioritized list of potential homes to the user.

Abstract: A method and system is presented for determining pupillary distance and multi-focal element height for prescription eyeglasses via images received through a computer network. The received image has a reference object of a known real-world size located approximately the same distance from the camera as the face. The size of the reference object on the image is determined, such as by measuring the number of pixels across the reference object. A scale for the image is determined by dividing the real world width of the reference object by the image size of the reference object. An image value for the pupillary distance and multi-focal element height is then determined. The scale value is applied to the image value to determine the real-world pupillary distance and multi-focal element height for the patient. The reference object can be a generally available object such as a monetary coin, or a facial element that has a relatively fixed size from face to face, such as the size of the iris.